Novoste Holding Line Against Guidant In Coronary Brachytherapy Market
This article was originally published in The Gray Sheet
Executive Summary
Novoste says its recall of 50 Beta-Cath brachytherapy transfer units due to incorrect calibration will contribute to a modest sales decline during the current quarter versus the fourth quarter of 2001